Keros Therapeutics, Inc. (KROS) Operating cash flow 2019–2025
Keros Therapeutics, Inc. (KROS) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
$107.5MFY2025 · since FY2019: -$16.0M → $107.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $107.5M | +166.8% |
| FY2024 | -$160.9M | -29.2% |
| FY2023 | -$124.5M | -77.7% |
| FY2022 | -$70.1M | -12.7% |
| FY2021 | -$62.1M | -68.5% |
| FY2020 | -$36.9M | -130.6% |
| FY2019 | -$16.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice